Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte Dreno

Showing results (171-180 of 213) with videos related to

Pageof 22
Sort By:
Journal of the American Academy of Dermatology|June 21, 2021
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, et al.
Frontiers in Oncology|November 8, 2023
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Stéphane Dalle, Olivier Dereure, et al.
European Journal of Dermatology : EJD|November 18, 2015
Defining and recognising locally advanced basal cell carcinomaJean Michel Amici, Maxime Battistella, Marie Beylot-Barry, et al.
The New England Journal of Medicine|August 10, 2007
A single cycle of rituximab for the treatment of severe pemphigusPascal Joly, Hugo Mouquet, Jean-Claude Roujeau, et al.
Cancers|July 2, 2021
Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaOndine Becquart, Bastien Oriano, Stéphane Dalle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Journal for Immunotherapy of Cancer|November 14, 2020
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapySylvain Simon, Valentin Voillet, Virginie Vignard, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2019
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohortPauline Tétu, Clara Allayous, Bastien Oriano, et al.
Pageof 22

Showing results (171-180 of 213) with videos related to

Sort By:
Pageof 22
Journal of the American Academy of Dermatology|June 21, 2021
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, et al.
Frontiers in Oncology|November 8, 2023
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Stéphane Dalle, Olivier Dereure, et al.
European Journal of Dermatology : EJD|November 18, 2015
Defining and recognising locally advanced basal cell carcinomaJean Michel Amici, Maxime Battistella, Marie Beylot-Barry, et al.
The New England Journal of Medicine|August 10, 2007
A single cycle of rituximab for the treatment of severe pemphigusPascal Joly, Hugo Mouquet, Jean-Claude Roujeau, et al.
Cancers|July 2, 2021
Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic MelanomaOndine Becquart, Bastien Oriano, Stéphane Dalle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2019
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung CancerBenjamin Dizier, Andrea Callegaro, Muriel Debois, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Journal for Immunotherapy of Cancer|November 14, 2020
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapySylvain Simon, Valentin Voillet, Virginie Vignard, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2019
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohortPauline Tétu, Clara Allayous, Bastien Oriano, et al.
Pageof 22